Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00016920
DRKS00016920
Not yet recruiting
Not Applicable

Retrospective analysis of imaging modalities acquired during clinical diagnosis of patients with clinical suspected neurodegenerative Parkinsonian syndrome - MOPET

Klinik und Poliklinik für Nuklearmedizin, LMU München0 sites50 target enrollmentMarch 18, 2019
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsG20Parkinson disease

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
G20
Sponsor
Klinik und Poliklinik für Nuklearmedizin, LMU München
Enrollment
50
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 18, 2019
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Klinik und Poliklinik für Nuklearmedizin, LMU München

Eligibility Criteria

Inclusion Criteria

  • •clinical suspected neurodegenerative Parkinsonian Syndrome and acquisition of at least one of the following modalities: cMRI, OCT, tau\-PET

Exclusion Criteria

  • •other non\-neurodegenerative CNS diseases like glioma or stroke

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Prospektive Evaluation von Multimodality Imaging Verfahren (PET - CT - MRT - US - Bildfusion) bei malignen Tumoren der Kopf-Hals-RegioPatients with malignant Head and Neck Tumors - Diagnostic Imaging StudyMedDRA version: 9.1Level: LLTClassification code 10049516Term: Malignant tumor
EUCTR2007-004393-81-ATMedizinische Universität Innsbruck - Universitätsklinik für Radiodiagnostik (Radiologie I)270
Completed
Not Applicable
Analysis of Imaging Features From Patients Treated With Brolucizumab in the Post-marketing Setting With Reports of Retinal Vasculitis and/or Retinal Vascular OcclusionIntraocular InflammationRetinal Vascular Occlusion
NCT05657158Novartis Pharmaceuticals198
Not yet recruiting
Phase 1
The dislocation of Jaw Joint is assessed using special CT.Health Condition 1: K088- Other specified disorders of teethand supporting structuresHealth Condition 2: M244- Recurrent dislocation of joint
CTRI/2020/12/029529OGITHA SRI S
Active, not recruiting
Phase 1
Phase 2a open label study of Fovista¿ (anti-PDGF agent) administered in combination with anti-VEGF therapy in subjects previously treated or treatment-naive.Subfoveal choroidal neovascularization secondary to Age-Related Macular Degeneration (AMD)MedDRA version: 20.0Level: PTClassification code 10071129Term: Neovascular age-related macular degenerationSystem Organ Class: 10015919 - Eye disordersMedDRA version: 20.1Level: LLTClassification code 10067791Term: Wet macular degenerationSystem Organ Class: 10015919 - Eye disordersTherapeutic area: Diseases [C] - Eye Diseases [C11]
EUCTR2015-000519-42-ITIVERIC bio, Inc.32
Active, not recruiting
Phase 1
Role of imaging in the evaluation of anatomic alterations in neovascular Age-Related Macular Degeneration (AMD) subjects: 18 month study of Fovista® (anti-PDGF therapy) administered in combination with anti-VEGF therapySubfoveal choroidal neovascularization secondary to Age-Related Macular Degeneration (AMD)MedDRA version: 18.0 Level: PT Classification code 10071129 Term: Neovascular age-related macular degeneration System Organ Class: 10015919 - Eye disordersMedDRA version: 18.0 Level: LLT Classification code 10067791 Term: Wet macular degeneration System Organ Class: 10015919 - Eye disordersTherapeutic area: Diseases [C] - Eye Diseases [C11]
EUCTR2015-000519-42-FROPHTHOTECH CORPORATIO32